Benzinga's Top #PreMarket Gainers

shares surged 86.14% to $1.88 in pre-market trading as Carl Icahn disclosed a 52.3% stake in the company.

shares gained 42.94% to $23.95 in the pre-market trading session after the company said a Phase Ib trial of its DX-2930 drug met safety goals and demonstrated statistically significant reductions in attack rates of hereditary angiodema, a rare disease.

shares climbed 10.25% to $8.28 in pre-market trading after the company reported that the results of a pharmacokinetic (PK) study support using a dose of 300 mg of XaraColl for phase 3 clinical studies in post-operative pain.

gained 7.30% to $14.25 in pre-market trading as the company named Edward Kaye as Interim CEO.

shares rose 5.29% to $97.50 in pre-market trading. UBS initiated coverage on Esperion Therapeutics with a Buy rating and a $140.00 price target.